Lacosamide Level of 10.8 µg/mL on 150mg BID: Appropriate but at Upper Threshold
A serum lacosamide concentration of 10.8 µg/mL on 150mg twice daily is technically within acceptable range but sits at the upper threshold where adverse effects become significantly more likely, and dose reduction should be strongly considered if any tolerability issues are present.
Clinical Context and Interpretation
Your patient's level of 10.8 µg/mL falls into a critical zone based on the most recent therapeutic drug monitoring data:
The traditional reference range of 10-20 mg/L (µg/mL) has been challenged by recent evidence 1. A 2023 study specifically examining lacosamide levels >10 mg/L found that 41% of patients experienced adverse effects at these concentrations, with a mean level of 15.6 mg/L in those with adverse effects versus 12.6 mg/L in those without (p=0.0495).
Most importantly, this same study recommends adjusting the upper therapeutic limit to 12 mg/L rather than 20 mg/L to achieve optimal efficacy while minimizing toxicity 1. Your patient's level of 10.8 µg/mL is approaching this revised threshold.
A 2024 Japanese study supports a more conservative approach, identifying an optimal therapeutic range of 8.0-10.5 µg/mL where effective cases showed significantly higher blood levels than ineffective cases, but without the toxicity seen at higher levels 2.
Dosing Considerations
The current regimen of 150mg BID (300mg total daily) producing a level of 10.8 µg/mL is consistent with expected pharmacokinetics:
- Lacosamide exhibits high bioavailability (100%) with low inter-patient variability (coefficients of variation <20%) 3
- The drug shows significant concentration fluctuations during the day under twice-daily dosing, with mean increases of 87.8% from trough to peak within 3 hours of dosing 4
- Your measured level of 10.8 µg/mL likely represents a trough or mid-interval concentration; peak levels could be substantially higher (potentially 15-20 µg/mL based on typical fluctuation patterns)
Actionable Recommendations
If the patient is tolerating therapy well without adverse effects:
- Continue current dose of 150mg BID
- Monitor closely for dizziness, somnolence, diplopia, or ataxia (most common adverse effects at these levels) 5, 6
- Consider switching to three-times-daily dosing (100mg TID) to reduce peak-to-trough fluctuations, which can improve tolerability 4
If any adverse effects are present (dizziness, somnolence, diplopia, ataxia):
- Reduce dose immediately - patients requiring dose reduction in the 2023 study had mean levels of 16.0 mg/L, but your patient at 10.8 mg/L is already in the zone where 41% experienced adverse effects 1
- Consider reduction to 100mg BID (200mg daily total) or 100mg TID
- Recheck level in 3-5 days after steady state is re-established (approximately 3 half-lives; lacosamide half-life is 13-16 hours) 3
Critical Pitfalls to Avoid
- Do not assume the 10-20 mg/L range is safe - this range was derived from peak measurements and does not reflect the toxicity threshold identified in recent therapeutic drug monitoring studies 1
- Timing of blood draw matters - if this level was drawn at peak (1-4 hours post-dose), the trough would be lower and more acceptable; if drawn at trough, peaks may be dangerously high 3, 4
- Concomitant sodium channel blockers increase toxicity risk - if your patient is on phenytoin, carbamazepine, or similar agents, adverse effects occur at lower lacosamide concentrations (median 5.1 µg/mL in one study) 6
- Enzyme-inducing AEDs lower lacosamide levels - phenytoin, carbamazepine, and phenobarbital reduce lacosamide concentrations by 20-26%, so higher doses may be needed if these are co-administered 6